ProCE Banner Activity

The Role of BRCA and Defective DNA Damage Repair

Slideset Download
In this downloadable slideset, Michael J. Pishvaian, MD, PhD, discusses the current data on using BRCA mutation status to identify patients for treatment with PARP inhibitors in select solid tumors.

Released: May 31, 2019

Expiration: May 29, 2020

No longer available for credit.

Share

Faculty

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Array BioPharma

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Foundation Medicine

Genentech TEXT Only

Loxo Oncology

Merck Oncology

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC